Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATCH Subprotocol J: Trastuzumab and Pertuzumab in HER2-Amplified Cancers
NCT06136897Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2017
- Primary completion
- Nov 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pertuzumab, trastuzumab in solid tumor, sponsored by National Cancer Institute. Started Mar 2017; status: active, not recruiting.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06136897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06136897.